NfL has been suggested as a potential biomarker in various neurodegenerative disorders including multiple sclerosis (MS), Alzheimer’s disease (AD), frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS) and Parkinsonian disorders [9,10,11]. This evidence concerns the gene NEFL and myeloid sarcoma.